Resources about TB
and TB Vaccine R&D
- Meeting Report: 6th Global Forum on TB Vaccines, 22 - 25 February 2022, published open access in Vaccine: X
- TB Vaccines Pipeline Report is a report from Treatment Action Group (TAG) that reviews progress in the clinical development of TB vaccines. The report is updated annually.
- Platforms in the TB Vaccine Pipeline provides an overview of the different platforms - or types of vaccines - in the TB vaccine pipeline
- Global Tuberculosis Report, published by the WHO, provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease at global, regional and country levels. The report is updated annually.
- TB Vaccine Development: The Next Chapter Starts Now is a webinar organized by Treatment Action Group and intended for the community, civil society, advocates, and other interested stakeholders. The webinar provides an overview of the TB vaccine pipeline, scientific challenges in TB vaccine development, and advocacy opportunities
- WHO Preferred Product Characteristics for New Tuberculosis Vaccine presents WHO preferences for new tuberculosis vaccines, driven by the high medical need for contribution to the fight against TB, in alignment with the End TB strategy.
- TB Vaccine Development Pathway, developed by IAVI and TBVI, is an online tool that provides a structured development path and gating criteria for TB vaccine candidates. It includes considerations for target populations, vaccine platforms, and market, access and implementation, as well as guidance for planning and operating community engagement activities.
- Ready Next Time is a report by Campaigns in Global Health that maps the intersection between efforts to strengthen pandemic prevention, preparedness and response (PPPR) systems and efforts to end TB. It sets out how policymakers and funders can deliver impact across both agendas, saving lives today and tomorrow and helping to make the case for sustained investment in public health.
- BCG World Atlas is an interactive map that provides detailed information on current and past BCG vaccination policies and practices for over 180 countries.
Resources for Advocacy, Policy, and Funding
- End TB Strategy from the World Health Organization’s Global TB Programme provides a 20-year strategy toward the goal of ending the TB epidemic, including research, development, and implementation of new tools.
- Global Plan to End TB 2023-2030 is a costed plan and roadmap for a concerted response to tuberculosis (TB) aligned with the WHO End TB Strategy, including a strategic framework for TB vaccine R&D.
- Report on Tuberculosis Research Funding Trends, published annually by TAG, tracks how much public, private, philanthropic, and multilateral institutions spend on TB research and development (R&D) across six areas of research: basic science, diagnostics, drugs vaccines, operational research, and infrastructure/unspecified projects.
- An investment case for new TB vaccines summarizes the results of a full value proposition for new tuberculosis (TB) vaccines commissioned by WHO to provide early evidence for national and global decision-makers involved in TB vaccine development and implementation, who include stakeholders involved in vaccine research, financing, regulation and policy-making, manufacturing, introduction and procurement. A Q&A on how this work can be best used for TB vaccine advocacy is available here.
- Words Matter, published by Stop TB Partnership, is a communications tool for partners, stakeholders, and anyone affected or working in TB. The guide is a key instrument to encourage positive change, sensitize, promote appropriate language, end the stigmatization, and empower people affected by TB.
- New TB vaccines needed to tackle AMR shares a collective call to decision-makers to prioritize TB vaccine R&D as a signature piece of global health and antimicrobial resistance (AMR) agendas. The brief, from the TB Vax ARM, draws on the latest research in health and economic modelling to demonstrate how new TB vaccines could significantly help control drug-resistant TB, in a cost-effective and affordable way.
- The Urgent Need for New TB Vaccines, published by the TB Vaccine Advocacy Roadmap (TBVaxARM), provides information and talking points about the importance of TB vaccines to meeting global targets to end TB and the need to invest in TB vaccine research and development.
- Modeling in TB vaccine development provides an overview of mathematical modeling for TB vaccines, like public health impact and cost-effective modeling, and how modeling can be used to support TB vaccine advocacy efforts.
- A Deadly Divide: TB Commitments vs TB Realities. Developed by the Stop TB Partnership Communities, Developing Country NGO, and Developed Country NGO Delegations to the Board with input from more than 1,000 civil society and affected community partners from 92 countries, this report lays out priorities and six calls to action that are required to end the TB epidemic.
- Video - Phumeza Tisile talk about her challenges in facing extensively drug-resistant TB, her vision of a TB free world, and how we can achieve it with new TB vaccines.
- Joint Statement: WHO Director-General and the Civil Society Task Force on TB, a call for increased political commitment and accountability in preparation for the 2023 UN High-Level Meeting on Tuberculosis.
- TB Research Investments Provide Returns in Combating Both TB and COVID-19 is a policy brief published by Treatment Action Group (TAG) that explores the impact of COVID-19 on TB research and development (R&D), and how tools, concepts, capacity, and infrastructure established through years of public and donor investments in TB R&D have informed and jump-started COVID-19 research and responses.
Contact us if you have resources related to advocacy, policy, and funding for TB vaccine R&D that you would like to share.
Resources for Community Engagement
- Good Participatory Practice Guidelines for TB Vaccine Research, published by Aeras, is a user- friendly framework that defines specific standards and key elements needed for creating effective partnerships with stakeholders throughout the entire research process.
- Frequently Asked Questions on TB Vaccine Research, published by IAVI, is a fact sheet that provides information and answers to commonly asked questions about TB vaccine research.
- Myths and Facts about TB Vaccine Research, by IAVI, is a fact sheet that responds to some common misconceptions about vaccine research.
- Tuberculosis Vaccines and Clinical Trials, published by IAVI, provides information about TB, vaccines, and clinical trials in an illustrative and easy to understand booklet.
- Being Part of Tuberculosis Vaccine Clinical Trials is a speaking book published by Books of Hope in collaboration with Aeras, that provides potential clinical trial participants with information about tuberculosis and what is involved in participating in a clinical trial. The information is in both English and Afrikaans.
Recent Scientific Publications
- Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? Larsen SE, Baldwin SL, Coler RN. Int J Infect Dis. 2023 May. doi: 10.1016/j.ijid.2023.03.035. Epub 2023 Mar 23.
- Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience. Saluzzo F, Espinosa-Pereiro J, Dressler S, Tàvora Dos Santos Filho E, Seidel S, Gonzalez Moreno J, Heinrich N, Sanchez-Montalva A, Cirillo DM. Int J Infect Dis. 2023 May. doi: 10.1016/j.ijid.2023.03.008. Epub 2023 Mar 9.
- Mechanisms of ag85a/b DNA vaccine conferred immunotherapy and recovery from Mycobacterium tuberculosis-induced injury. Wang N, Liang Y, Ma Q, Mi J, Xue Y, Yang Y, Wang L, Wu X. Immun Inflamm Dis. 2023 May.doi: 10.1002/iid3.854
- Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study. Mao JJ, Zang X, Yue WL, Zhai PY, Zhang Q, Li CH, Zhuang X, Liu M, Qin G. BMJ Glob Health. 2023 May. doi: 10.1136/bmjgh-2023-012306.
- A VLP-Based Vaccine Displaying HBHA and MTP Antigens of Mycobacterium tuberculosis Induces Protective Immune Responses in M. tuberculosis H37Ra Infected Mice. Wang J, Xie T, Ullah I, Mi Y, Li X, Gong Y, He P, Liu Y, Li F, Li J, Lu Z, Zhu B. Vaccines (Basel). 2023 May 4. doi: 10.3390/vaccines11050941.
- Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria. Murphy M, Suliman S, Briel L, Veldtsman H, Khomba N, Africa H, Steyn M, Snyders CI, van Rensburg IC, Walzl G, Chegou NN, Hatherill M, Hanekom WA, Scriba TJ, Nemes E. Int J Infect Dis. 2023 May. doi: 10.1016/j.ijid.2023.02.018. Epub 2023 Feb 25.
- Development of peptide vaccine candidate using highly antigenic PE-PGRS family proteins to stimulate the host immune response against Mycobacterium tuberculosis H37Rv: an immuno-informatics approach. Kumar A, Sharma P, Arun A, Meena LS. J Biomol Struct Dyn. 2023 May. doi: 10.1080/07391102.2022.2048079. Epub 2022 Mar 16.
- Advances in development of new tuberculosis vaccines. da Costa C, Onyebujoh P, Thiry G, Zumla A. Curr Opin Pulm Med. 2023 May 1. doi: 10.1097/MCP.0000000000000950. Epub 2023 Mar 2.
- The tuberculosis vaccine challenge. Bull World Health Org. 2023 May 1. doi: 10.2471/BLT.23.02053.
- BCG is protective against death in male but not female patients with pulmonary tuberculosis in Guinea-Bissau. Bohlbro AS, Mendes AM, Sifna A, Patsche CB, Soelberg MES, Gomes V, Wejse C, Rudolf F. Trans R Soc Trop Med Hyg. 2023 May 2. doi: 10.1093/trstmh/trac120.
- Role of B Cells in Mycobacterium Tuberculosis Infection. Stewart P, Patel S, Comer A, Muneer S, Nawaz U, Quann V, Bansal M, Venketaraman V. Vaccines (Basel). 2023 May 6. doi: 10.3990/vacciness11050955.
- BCG∆BCG1419c and BCG differ in induction of autophagy, c-di-GMP content, proteome, and progression of lung pathology in Mycobacterium tuberculosis HN878-infected male BALB/c mice. Aceves-Sánchez MJ, Barrios-Payán JA, Segura-Cerda CA, Flores-Valdez MA, Mata-Espinosa D, Pedroza-Roldán C, Yadav R, Saini DK, de la Cruz MA, Ares MA, Bielefeldt-Ohmann H, Baay-Guzmán G, Vergne I, Velázquez-Fernández JB, Barba León J, Hernández-Pando R. Vaccine. 2023 May 8. doi: 10.1016/j.vaccine.2023.04.065. Online ahead of print.
- A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG. Dijkman K, Lindenstrøm T, Rosenkrands I, Søe R, Woodworth JS, Lindestam Arlehamn CS, Mortensen R. NPJ Vaccines. 2023 May 9. doi: 10.1038/s41541-023-00666-2.
- Safety and Immunogenicity of the ID93 + GLA-SE Tuberculosis Vaccine in BCG-Vaccinated Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Choi YH, Kang YA, Park KJ, Choi JC, Cho KG, Ko DY, Ahn JH, Lee B, Ahn E, Woo YJ, Jung K, Kim NY, Reese VA, Larsen SE, Baldwin SL, Reed SG, Coler RN, Lee H, Cho SN. Infect Dis Ther. 2023 May 11. doi: 10.1007/s40121-023-00806-0. Online ahead of print.
- Role of MAIT cells in immunity against Mycobacterium tuberculosis. [Article in Chinese]. Cao ZH, Cheng XX.Zhonghua Jie He He Hu Xi Za Zhi. 2023 May 12. doi: 10.3760/cma.j.cn112147-20230307-00117.
- Host genetic background is a barrier to broadly effective vaccine-mediated protection against tuberculosis. Lai R, Gong DN, Williams T, Ogunsola AF, Cavallo K, Arlehamn CSL, Acolatse S, Beamer G, Ferris MT, Sassetti CM, Lauffenburger DA, Behar SM. J Clin Invest. 2023 May 18. doi: 10.1172/JCI167762.
- A candidate subunit vaccine induces protective immunity against Mycobacterium avium subspecies paratuberculosis in mice. Shao M, Cui N, Tang Y, Chen F, Cui Y, Dang G, Liu S. NPJ. 2023 May 20. doi: 10.1038/s41541-023-00675-1.
- Vaccines against Tuberculosis: Where Are We Now? Srivastava S, Dey S, Mukhopadhyay S. Vaccine (Basel). 2023 May 22. doi: 10.3390/vaccines11051013.
- Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates. Wang R, Fan X, Jiang Y, Li G, Li M, Zhao X, Luan X, Deng Y, Chen Z, Liu H, Wan K. Vaccines. 2023 May 22. doi: 10.1016/j.vaccine.2023.04.003. Online ahead of print.
- Airway T cells are a correlate of i.v. Bacille Calmette-Guerin-mediated protection against tuberculosis in rhesus macaques. Darrah PA, Zeppa JJ, Wang C, Irvine EB, Bucsan AN, Rodgers MA, Pokkali S, Hackney JA, Kamath M, White AG, Borish HJ, Frye LJ, Tomko J, Kracinovsky K, Lin PL, Klein E, Scanga CA, Alter G, Fortune SM, Lauffenburger DA, Flynn JL, Seder RA, Maiello P, Roederer M. Cell Host Microbe. 2023 May 23. doi: 10.1016/j.chom.2023.05.006. Online ahead of print.
- Heterologous production of the D-cycloserine intermediate O-acetyl-L-serine in a human type II pulmonary cell model. Robbins L, Balaram A, Dejneka S, McMahon M, Najibi Z, Pawlowicz P, Conrad, WH. Sci Rep. 2023 May 26. doi: 10.1038/s41598-023-35632-4.
- Non-restrictive open vial policy combined with the home visit vaccinations for improving BCG coverage in a high-incidence outreach region: A model-based cost-effectiveness analysis for Indonesia. Machlaurin A, Luttjeboer J, Setiawan D, van der Werf TS. Postma MJ. J Glob Health. 2023 May 26. doi: 10.7189/jogh.13.04049.
- Mycobacterial Genetic Technologies for Probing the Host-Pathogen Microenvironment. Adefisayo OO, Curtis ER, Smith CM. Infect Immun. 2023 May 30. doi: 10.1128/iai.00430-22. Online ahead of print.
Contact us with recent publications (within last 30 days) sharing new data, approaches, and information on TB vaccine R&D